Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5819324 | 0.78 | LPL (0.36) | MAPTPOLBKMT2AALDH1A1KDM4E | |
| SCHEMBL18481933 | 0.77 | SIRT2 (0.36) | MAPTPOLBTP53ALDH1A1KDM4E | |
| SCHEMBL17179284 | 0.74 | GAA (0.48) | MAPTMEN1POLBKMT2ATP53 | |
| SCHEMBL4555957 | 0.73 | KMT2A (0.35) | MAPTMEN1POLBKMT2ANPC1 | |
| SCHEMBL4555136 | 0.73 | KMT2A (0.35) | MAPTMEN1POLBKMT2ANPC1 | |
| SCHEMBL17179225 | 0.71 | IDO1 (0.45) | MAPTALDH1A1GAAHTTHTR2C | |
| SCHEMBL5820664 | 0.70 | TLR9 (0.52) | — | |
| SCHEMBL6539867 | 0.69 | AR (0.38) | MAPTMEN1POLBKMT2ATP53 | |
| SCHEMBL4866562 | 0.68 | HSP90AA1 (0.34) | MAPTMEN1POLBKMT2ANPC1 | |
| SCHEMBL21948628 | 0.67 | IDO1 (0.39) | GAAHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | MAPT 150/4885MEN1 2684/4885POLB 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.